A Double-blind, Randomized, Placebo-controlled Phase II Pilot Trial Investigating Efficacy, Safety and Feasibility of 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition by AZD4017 to Improve Skin Function and Wound Healing in Patients With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2018
At a glance
- Drugs AZD 4017 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GC-SHealD
- 10 May 2018 Planned End Date changed from 30 Jun 2018 to 28 Sep 2018.
- 10 May 2018 Planned primary completion date changed from 1 Jun 2018 to 12 Sep 2018.
- 10 May 2018 Status changed from active, no longer recruiting to recruiting.